ПРОСТАТА БЕЗИ САРАТОНИНИНГ ЮРАК ҚОН-ТОМИР ТИЗИМИ КАСАЛЛИКЛАРИ ВА 2-ТИП ҚАНДЛИ ДИАБЕТ БИЛАН ЎЗАРО БОҒЛИҚЛИГИ

Abdollah F., Sammon J.D., Reznor G., et al. Medical androgen deprivation therapy and increased non-cancer mortality in nonmetastatic prostate cancer patients aged ≥66 years // Eur J Surg Oncol. 2015. Vol. 41, N 11. P. 1529–1539.

Abi Khalil C. The emerging role of epigenetics in cardiovascular disease // Ther Adv Chronic Dis. 2014. Vol. 5, N 4. P. 178–187.

Aggarwal B.B., Shishodia S., Sandur S.K., et al. Inflammation and cancer: how hot is the link? // Biochem Pharmacol. 2006. Vol. 72, N 11. P. 1605–1621. doi: 10.1016/j.bcp.2006.06.029

Albanes D, Weinstein SJ, Wright ME, et al. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst. 2009;101:1272-1279.

Allott E.H., Masko E.M., Freedland S.J. Obesity and prostate cancer: Weighing the evidence // Eur Urol. 2013. Vol. 63, N 5. P. 800–809.

Arcidiacono B, Iiritano S, Nocera A, et al. Insulin Resistance and Cancer Risk: An Overview of the Pathogenetic Mechanisms. Exp Diabetes Res. 2012;2012:1-12.

Asia Pacific Cohort Studies Collaboration; Huxley R., Ansary-Mohaddam A., et al. The impact of modifiable risk factors on mortality from prostate cancer in populations of the Asia-Pacific region // Asian Pac J Cancer Prev. 2007. Vol. 8, N 2. P. 199–205.

Attner B, Landin-OlssonM, LithmanT, et al. Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden. Cancer Causes Control. 2012;23(5):769-777

Bansal D, Bhansali A, Kapil G, et al. Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 2013;16(2):151-158.

Batty G.D., Kivimaki M., Clarke R., et al. Modifiable risk factors for prostate cancer mortality in London. forty years of follow-up in the Whitehall study // Cancer Causes Control. 2011. Vol. 22, N 2. P. 311–318.

Bhatia N., Santos M., Jones L.W., et al. Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer // Circulation. 2016. Vol. 133, N 5. P. 537–541.

Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia. 2004;47(6):1071-1078.

Cattabiani C, Basaria S, Ceda GP. Luci, et al. Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men. J Endocrinol Invest. 2012;35:104-120.

Chen Y, Chen Q, Wang Z, Zhou J. Insulin Therapy and Risk of Prostate Cancer: a Systematic Review and Meta-Analysis of Observational Studies. PLoSOne. 2013;8(11):e81594.

Cheng C., Geng F., Cheng X., Guo D. Lipid metabolism reprogramming and its potential targets in cancer // Cancer Commun (Lond). 2018. Vol. 38, N 1. P. 27.

Dankner R, Boffetta P, Balicer RD, et al. Time-dependent Risk of cancer after a diabetes diagnosis in a cohort of 2.3 million adults. Am J Epidemiol. 2016;183(12):1098-1106.

Darbinian JA, Ferrara AM, Van Den Eeden SK, et al. Glycemic status and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:628-635.

Davis M.K., Rajala J.L., Tyldesley S., et al. The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada // J Oncol.2015. N 2015. P. 820403.

de Nigris F., Sica V., Herrmann J., et al. c-Myconcoprotein: cell cycle-related events and new therapeutic challenges in сancer and cardiovascular disease // Cell Cycle. 2003. Vol. 2, N 4. P. 325–328.

Di Francesco S., Robuffo I., Caruso M., et al. Metabolic Alterations, Aggressive Hormone-NaпveProstate Cancer and Cardiovascular Disease: A Complex Relationship // Medicina (Kaunas). 2019. Vol. 55, N 3. P. 62. doi: 10.3390/medicina55030062

Di Sebastiano KM, Bell KE, Mitchell AS, et al. Glucose metabolism during the acute prostate cancer treatment trajectory: The influence of age and obesity. Clin Nutr. 2018;37(1):195-203. https://doi.org/10.1016/j.clnu.2016.11.024

Di Sebastiano KM, Pinthus JH, DuivenvoordenWCM, et al. Elevated c-peptides, abdominal obesity and abnormal adipokine profile are associated with higher Gleason scores in prostate cancer. Prostate. 2017;77:211-221. https://doi.org/10.1002/pros.23262

Dixon S., Stockwell B.R. The role of iron and reactive oxygen species in cell death // Nat ChemBiol. 2014. Vol. 10, N 1. P. 9–17. doi: 10.1038/nchembio.1416

Fall K, Garmo H, Gudbjornsdottir S, et al. Diabetes mellitus and prostate cancer risk; a nation wide case-control study within PCBaSe Sweden. Cancer Epidemiol Biomarkers Prev. 2013;22(6):1102-1109

Farwell W.R., D’Avolio L.W., Scranton R.E., et al. Statins and prostate cancer diagnosis and grade in a veterans population // J Natl Cancer Inst. 2011. Vol. 103, N 11. P. 885–892.

Galbraith L., Leung H.Y., Ahmad I. Lipid pathway deregulation in advanced prostate cancer // Pharmacol Res. 2018. N 131. P. 177–184.

Hager M., Mikuz G., Bartsch G., et al. The association between local atherosclerosis and prostate cancer // BJU Int. 2007. Vol. 99, N 1. P. 46–48. doi: 10.1111/j.1464-410X.2006.06549.x

Jian Gang P, Mo L, Lu Y, et al. Diabetes mellitus and the risk of prostate cancer: an update and cumulative meta-analysis. Endocr Res. 2015;40(1):54-61.

Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2056-2062.

Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448-4456.

Khan M.A., Hashim M.J., Mustafa H., et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study // Cureus. 2020. Vol. 12, N 7. P. e9349.

Kitahara C.M., Berrington de Gonzalez A., Freedman N.D., et al. Total cholesterol and cancer risk in a large prospective study in Korea // J ClinOncol. 2011. Vol. 29, N 12. P. 1592–1598.

Lai GY, Park Y, Hartge P, et al. The association between selfreported diabetes and cancer incidence in the NIH-AARP diet and health study. J ClinEndocrinol Metab. 2013;98(3):E497-E502.

Lawrence YR, Morag O, Benderly M, et al. Association between metabolic syndrome, diabetes mellitus and prostate cancer risk. Prostate Cancer Prostatic Dis. 2013;16(2):181-186.

Libby P. Mechanisms of acute coronary syndromes and their implications for therapy // N Engl J Med. 2013. Vol. 368, N 21. P. 2004–2013.

Magliano DJ, Davis WA, Shaw JE, et al. Incidence and predictors of all-cause and site-specific cancer in type 2 diabetes: the Fremantle diabetes study. Eur J Endocrinol. 2012;167(4):589-599.

Matthes K.L., Pestoni G., Korol D., et al. The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study // UrolOncol. 2018. Vol. 36, N 6. P. 309.e15–309.e23.

Mondul A.M., Clipp S.L., Helzlsouer K.J., PlatzE.A. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort // Cancer Causes Control. 2010. Vol. 21, N 1. P. 61–68.

Moses K A, Utuama O A, Goodman M, et al. The association of diabetes and positive prostate biopsy in a US veteran population Prostate Cancer. ProstaticDis. 2012;15(1):70-74

Ouimet M. Autophagy in obesity and atherosclerosis: Interrelationships between cholesterol homeostasis, lipoprotein metabolism and autophagy in macrophages and other systems // Biochim Biophys Acta. 2013. Vol. 1831, N 6. P. 1124–1133.

Pelton K., Freeman M.R., Solomon K.R. Cholesterol and Prostate Cancer // Curr OpinPharmacol. 2012. Vol. 12, N 6. P. 751–759. doi: 10.1016/j.coph.2012.07.006

Perks CM, Zielinska HA, Wang J, et al. Insulin receptor isoform variations in prostate cancer cells. Front Endocrinol. 2016;7:132.

Platz E.A., Clinton S.K., Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era // Int J Cancer. 2008. Vol. 123, N 7. P. 1693–1698.

Preston MA, Riis AH, Ehrenstein V, et al. Metformin use and prostate cancer risk. Eur Urol. 2014;66:1012-1020.

Ross S., Stagliano N.E., Donovan M.J., et al. Atherosclerosis and cancer: common molecular pathway of disease development and progression // Ann N Y Acad Sci. 2001. N 947. P. 271–292. Discussion 292–293.

Roth G.A., Johnson C., Abajobir A., et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015 // J Am CollCardiol. 2017. Vol. 70, N 1. P. 1–25.

Samueal VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest 2016;1(26):12-22.

Sarrazy V., Sore S., Viaud M., et al. Maintenance of macrophage redox status by ChREBP limits inflammation and apoptosis and protects against advanced atherosclerotic lesion formation // Cell Rep. 2015. Vol. 13, N 1. P. 132–144.

Shafique K., McLoone P., Qureshi K., et al. Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years’ follow up // BMC Cancer. 2012. N 12. P. 25.

Shin D.W., Ahn E., Kim H., et al. Non-cancer mortality among long-term survivors of adult cancer in Korea: national cancer registry study // Cancer Causes Control. 2010. Vol. 21, N 6. P. 919–929.

Shakhanova Sh. Sh., Rakhimov M. N. Aspects of sarcopenia syndrome in oncological practice: diagnosis and treatment (literature review) // Journal of Biomedicine and Practice. 2023, vol. 8, issue 3, pp. 406-417

Simons K., Vaz W.L. Model systems, lipid rafts, and cell membranes // Annu Rev Biophys BiomolStruct. 2004. N 33. P. 269–295.

Sosa V., Molinй T., Somoza R., et al. Oxidative stress and cancer: An Overview // Ageing Res Rev. 2013. Vol. 12, N 1. P. 376–390.

Sung H., Ferlay J., Siegel R.L., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer J Clin. 2021. Vol. 71,N 3. P. 209–249.

Tall A.R., Yvan-Charvet L. Cholesterol, inflammation and innate immunity // Nat Rev Immunol. 2015. Vol. 15, N 2. P. 104–116.

Tapia-Vieyra J.V., Delgado-Coello B., Mas-Oliva J. Atherosclerosis and Cancer; A Resemblance with Far-reaching Implications // Arch Med Res. 2017. Vol. 48, N 1. P. 12–26.

Tekdoğan UY, Bağcioğlu M, Özcan S, et al. The effect of oral glucose tolerance test on insulin and some related indicators in elderly male patients with prostate cancer and benign prostate hyperplasia. Turkish J Geriatrics. 2015;18:10-14.

Thomas J.A. 2nd, Gerber L., Baсez L.L., et al. Prostate Cancer Risk in Men with Baseline History of Coronary Artery Disease: Results from the REDUCE Study // Cancer Epidemiol Biomarkers Prev. 2012. Vol. 21, N 4. P. 576–581.

Tosi M.R., Bottura G., Lucchi P., et al. Cholesteryl esters in human malignant neoplasms // Int J MolMed. 2003. Vol. 11, N 1. P. 95–98. doi: 10.3892/ijmm.11.1.95

Tsilidis KK, Allen NE, Appleby PN, et al Diabetes mellitus and risk of prostate cancer in the European prospective investigation into cancer and nutrition Int J Cancer. 2015;136(2):372-381.

Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607.

Van Hemelrijck M., Garmo H., Holmberg L., et al. Prostate cancer risk in the Swedish AMORIS study. the interplay among triglycerides, total cholesterol, and glucose // Cancer. 2011. Vol. 117, N 10. P. 2086–2095.

Van Hemelrijck M., Walldius G., Jungner I., et al. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study // Cancer Causes Control. 2011. Vol. 22, N 7. P. 1011–1019.

Vidal-Vanaclocha F. Inflammation in the molecular pathogenesis of cancer and atherosclerosis // Reumatol Clin. 2009. Vol. 5, Suppl. 1. P. 40–43.

Virmani R., Kolodgie F.E., Burke A.P., et al. Atherosclerotic plaque progression and vulnerability to rupture angiogenesis as a source of intraplaquehemorrhage // Arterioscler Thromb Vasc Biol. 2005. Vol. 25, N 10. P. 2054–2061.

Wallis C.J., Mahar A.L., Satkunasivam R., et al. Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation // Urology. 2016. N 97. P. 145–152.

Writing Group Members; Mozaffarian D., Benjamin E.J., et al. Heart disease and stroke statistics-2016 update: A report from the American Heart Association // Circulation. 2016. Vol. 133, N 4. P. e38–360.

Yadav L., Puri N., Rastogi V., et al. Tumourangiogenesis and angiogenic inhibitors: a review // J Clin Diagn Res. 2015. Vol. 9, N 6. P. XE01–XE05.

Yusuf S., Rangarajan S., Teo K., et al., Cardiovascular risk and events in 17 low-, middle-, and high-income countries // N Engl J Med. 2014. Vol. 371, N 9. P. 818–827.

Zamboni PF, Simone M, Passaro A, et al. Metabolic profile in patients with benign prostate hyperplasia or prostate cancer and normal glucose tolerance. Horm Metab Res. 2003;35:296-300.

Zaorsky N.G., Churilla T.M., Egleston B.L., et al. Causes of death among cancer patients // Ann Oncol. 2017. Vol. 28, N 2. P. 400–407.

Zhang X., Li G., Hu L., et al. Resistive index of prostatic capsular arteries as a predictor of prostate cancer in patients undergoing initial prostate biopsy // Med Oncol. 2014. Vol. 31, N 12. P. 297.

Zhivotovsky B., Orrenius S. Cell cycle and cell death in disease: past, present and future // J Intern Med. 2010. Vol. 268, N 5. P. 395–409.

Статья поступила в редакцию 05.11.2023; одобрена после рецензирования 23.12.2023; принята к публикации 25.12.2023.

The article was submitted 05.11.2023; approved after reviewing 23.12.2023; accepted for publication 25.12.2023.

Информация об авторах:

Тилляшайхов Мирзаголиб Нигматович- д.м.н., профессор. Директор Республиканского специализированного научно-практического медицинского центра онкологии и радиологии МЗ РУз, Республика Узбекистан, Ташкент. E-mail: tmirza58@mail.ru, https://orcid.org/0009-0001-2859-5291

Алимов Жалолиддин Усмонхон угли- базовый докторант кафедры Урологии Самаркандского Государственного Медицинского Университета, Республика Узбекистан, Самарқанд. E-mail: jaloliddin.urology@gmail.com, https://orcid.org/0009-0009-3959-9878

Источники финансирования: Работа не имела специального финансирования.

Конфликт интересов: Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.

Вклад авторов:

Тилляшайхов Мирзаголиб Нигматович — идеологическая концепция работы, написание текста;

Алимов Жалолиддин Усмонхон угли — сбор и анализ источников литературы, написание текста, редактирование статьи;

Information about the authors:

Information about the authors:

Tillyashaykhov Mirzagolib Nigmatovich - MD, Professor. Director of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology of the Ministry of Health of the Republic of Uzbekistan, Tashkent. E-mail: tmirza58@mail.ru, .https://orcid.org/0009-0001-2859-5291

Alimov Jaloliddin Usmonkhon ugli - basic doctoral student of the Department of Urology of Samarkand State Medical University, Republic of Uzbekistan, Samarkand.E-mail: jaloliddin.urology@gmail.com, https://orcid.org/0009-0009-3959-9878

Sources of funding: The work did not receive any specific funding.

Conflict of interest: The authors declare no explicit or potential conflicts of interest associated with the publication of this article.

Contribution of the authors:

Tillyashaykhov Mirzagolib Nigmatovich - ideological concept of the work, writing the text;

Alimov Jaloliddin Usmonkhon ugli - analysis of literature sources; collection and analysis of the material.writing the text; editing the article